Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT5L2VC)

• DTT Name: Kallikrein-related peptidase (KLK) DTT Info
• Gene Name: KLK

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[1]
Cetraxate	DMSP4JX	Peptic ulcer	DA61	Approved	[2]
Ecallantide	DMOF2C6	Retina venous occlusion	9B74.1	Approved	[3]

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LM-030	DMSJOE3	Congenital ichthyosiform erythroderma	EC20.02	Phase 2	[4]

4 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzoxazinone derivative 2	DM4FHTG	N. A.	N. A.	Patented	[5]
Benzyl amine derivative 1	DMOU84B	N. A.	N. A.	Patented	[5]
Benzyl amine derivative 2	DMFK7EL	N. A.	N. A.	Patented	[5]
Heteroaryl-carboxamide derivative 11	DM1CWU7	N. A.	N. A.	Patented	[5]

References

• [1] Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
• [2] A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48.
• [3] Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.